TG Therapeutics (NASDAQ:TGTX) Stock Rating Reaffirmed by Cantor Fitzgerald

TG Therapeutics (NASDAQ:TGTX – Get Rating)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a research note issued to investors on Monday, Zacks.com reports. Cantor Fitzgerald also issued estimates for TG Therapeutics’ FY2022 earnings at ($3.60) EPS.

Several other equities research analysts have also issued reports on the company. Zacks Investment Research raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 26th. StockNews.com assumed coverage on TG Therapeutics in a research report on Thursday, March 31st. They set a “sell” rating for the company. HC Wainwright decreased their target price on TG Therapeutics from $68.00 to $19.00 and set a “buy” rating for the company in a research report on Monday, April 18th. Finally, B. Riley decreased their target price on TG Therapeutics from $35.00 to $23.00 and set a “buy” rating for the company in a research report on Tuesday, April 19th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $22.75.

Shares of TGTX opened at $5.71 on Monday. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.28. The business’s fifty day moving average is $8.62 and its 200 day moving average is $15.12. TG Therapeutics has a 12-month low of $5.58 and a 12-month high of $41.00. The stock has a market cap of $824.82 million, a P/E ratio of -2.17 and a beta of 2.25.

TG Therapeutics (NASDAQ:TGTX – Get Rating) last issued its quarterly earnings data on Tuesday, March 1st. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.08). TG Therapeutics had a negative net margin of 5,204.07% and a negative return on equity of 101.11%. The company had revenue of $2.32 million for the quarter, compared to the consensus estimate of $9.90 million. During the same quarter last year, the business posted ($0.71) earnings per share. On average, analysts expect that TG Therapeutics will post -2.11 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in TGTX. Moors & Cabot Inc. purchased a new stake in TG Therapeutics in the 3rd quarter worth about $53,000. Exane Derivatives purchased a new position in TG Therapeutics during the 1st quarter valued at about $54,000. Baldwin Brothers LLC MA grew its holdings in TG Therapeutics by 250.0% during the 1st quarter. Baldwin Brothers LLC MA now owns 7,000 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 5,000 shares in the last quarter. PSI Advisors LLC purchased a new position in TG Therapeutics during the 3rd quarter valued at about $70,000. Finally, Prospera Financial Services Inc purchased a new position in TG Therapeutics during the 1st quarter valued at about $70,000. 70.52% of the stock is owned by institutional investors.

About TG Therapeutics (Get Rating)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.

Featured Articles